Allison E Burnett
Overview
Explore the profile of Allison E Burnett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khalife R, Burnett A, Tritschler T, Waldron B, Xu Y
BMJ
. 2024 Aug;
386:e079520.
PMID: 39214564
No abstract available.
2.
Triller D, Wilson A, Allen A, Burnett A, Gouveia-Pisano J, Brenner A, et al.
J Thromb Thrombolysis
. 2023 Oct;
57(1):107-116.
PMID: 37839023
Direct oral anticoagulants (DOAC) are the most widely prescribed oral anticoagulants in the United States. Despite advantages over warfarin, system-level improvements are needed to optimize outcomes. While Veterans Health Administration...
3.
Burnett A, Barnes G, Allen A, Ansell J, Blumenstein M, Connors J, et al.
J Am Geriatr Soc
. 2023 Sep;
71(12):3951-3953.
PMID: 37702478
No abstract available.
4.
Silva F, Burnett A, Padmanabhan A, Rollins-Raval M, Splinter N, Desai M
Thromb J
. 2023 Apr;
21(1):46.
PMID: 37085884
Background: There are very few documented reports in literature of cerebral venous sinus thrombosis (CVST) caused by immune-mediated heparin-induced thrombocytopenia (HIT). Further, there are very few reports of false negative...
5.
Porres-Aguilar M, Ansell J, Mukherjee D, Cota-Rangel X, Martinez-Zubieta R, Carrillo-Esper R, et al.
Arch Med Res
. 2022 Dec;
54(1):1-6.
PMID: 36481128
Antithrombotic therapies, especially anticoagulants, are high-risk medications with increased potential for adverse events. The development and implementation of a well-functioning, designated, multidisciplinary anticoagulation stewardship program (MASP), tailored to each hospital-center's...
6.
Burnett A, Barnes G
Res Pract Thromb Haemost
. 2022 Jul;
6(5):e12757.
PMID: 35865732
No abstract available.
7.
Meador S, Dyke S, Togami J, Kuskov B, Burnett A
J Thromb Thrombolysis
. 2021 Aug;
53(2):436-445.
PMID: 34410560
Antithrombotic therapies include anticoagulants and antiplatelet agents. It is increasingly recognized that combined dual antithrombotic (DAT, which consists of an oral anticoagulant and a single antiplatelet) and triple antithrombotic therapies...
8.
Darzi A, Repp A, Spencer F, Morsi R, Charide R, Etxeandia-Ikobaltzeta I, et al.
Blood Adv
. 2020 Oct;
4(19):4929-4944.
PMID: 33049056
Multiple risk-assessment models (RAMs) for venous thromboembolism (VTE) in hospitalized medical patients have been developed. To inform the 2018 American Society of Hematology (ASH) guidelines on VTE, we conducted an...
9.
Raval J, Burnett A, Rollins-Raval M, Griggs J, Rosenbaum L, Nielsen N, et al.
Transfusion
. 2020 May;
60(6):1131-1132.
PMID: 32374920
No abstract available.
10.
Schunemann H, Cushman M, Burnett A, Kahn S, Beyer-Westendorf J, Spencer F, et al.
Blood Adv
. 2018 Nov;
2(22):3198-3225.
PMID: 30482763
Background: Venous thromboembolism (VTE) is the third most common vascular disease. Medical inpatients, long-term care residents, persons with minor injuries, and long-distance travelers are at increased risk. Objective: These evidence-based...